Aprea Therapeutics Inc Total Liabilities
Aprea Therapeutics Inc total liabilities. Based on the latest financial reports, Aprea Therapeutics Inc (APRE) has total liabilities worth $3.82 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Aprea Therapeutics Inc (APRE) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Aprea Therapeutics Inc (2007–2025)
Total liabilities of Aprea Therapeutics Inc from 2007 to 2025. This chart illustrates how Aprea Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Aprea Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Aprea Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Foresight Group Holdings Limited
LSE:FSG
|
UK | GBX79.08 Million |
|
Xylo Technologies Ltd.
NASDAQ:XYLO
|
USA | $19.96 Million |
|
Saxlund Group AB
ST:SAXG
|
Sweden | Skr75.97 Million |
|
EXPLOITS DISCOVERY CORP.
F:634
|
Germany | €320.26K |
|
Hwa Tai Industries Bhd
KLSE:8478
|
Malaysia | RM73.95 Million |
|
Innelec Multimedia
PA:ALINN
|
France | €62.68 Million |
|
Ambipar Emergency Response
NYSE MKT:AMBI
|
USA | $4.29 Billion |
|
In-Touch Survey Systems Ltd.
V:INX
|
Canada | CA$4.08 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Aprea Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see APRE total assets.
Liquidity & Leverage Metrics
Aprea Therapeutics Inc Total Liabilities Ratios Explained
Aprea Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aprea Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aprea Therapeutics Inc (2007–2025)
The table below shows the annual total liabilities of Aprea Therapeutics Inc from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.49 Million | -25.26% |
| 2024-12-31 | $4.67 Million | +6.53% |
| 2023-12-31 | $4.39 Million | -2.80% |
| 2022-12-31 | $4.51 Million | -38.33% |
| 2021-12-31 | $7.32 Million | -52.52% |
| 2020-12-31 | $15.41 Million | +64.56% |
| 2019-12-31 | $9.36 Million | -92.03% |
| 2018-12-31 | $117.46 Million | +94.06% |
| 2017-12-31 | $60.53 Million | +962.73% |
| 2013-12-31 | $5.70 Million | +8.29% |
| 2012-12-31 | $5.26 Million | +116.51% |
| 2007-12-31 | $2.43 Million | -- |
About Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tum… Read more